Why These 15 Large-Cap Stocks Are Plunging So Far In 2025

Page 3 of 14

12. Viatris Inc (NASDAQ:VTRS)

Number of Hedge Fund Holders In Q4 2024: 48

Viatris Inc (NASDAQ:VTRS) is a healthcare company. It provides access to generic and branded medicines, biosimilars, and active pharmaceutical ingredients.

The stock is down significantly so far in 2025. In December 2024, the FDA issued a warning letter and import alert for Viatris’ Indore manufacturing facility in India due to regulatory compliance issues.

This impacted 11 actively distributed products, including lenalidomide and everolimus, with exceptions granted for only four products due to shortage concerns.

The company estimates this will reduce 2025 revenues by $500 million and adjusted EBITDA by $385 million.

On top of that, Viatris reported fourth-quarter revenues of $3.52 billion, down 8% year-over-year. It missed consensus estimates of $3.61 billion. Adjusted EPS was $0.54 and also missed expectations of $0.57.

2025 guidance also came in lower than expected. Viatris projected 2025 revenues between $13.5 billion and $14 billion, below consensus expectations of $14.3 billion. Adjusted EPS guidance of $2.12-$2.26 also fell short of the consensus estimate of $2.60.

The consensus price target of $11 implies 16.03% upside.

VTRS stock is down 23.86% year-to-date.

Page 3 of 14